Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576042 | 0.90 | TP53 (0.65) | RAB9ANPC1SMN1; SMN2GRIN2BTP53 | |
| SCHEMBL1574803 | 0.89 | RAB9A (0.71) | RAB9ANPC1GRIN2BTP53THRB | |
| SCHEMBL1575500 | 0.88 | RAB9A (0.73) | RAB9ANPC1GRIN2BTP53THRB | |
| SCHEMBL1574587 | 0.88 | RAB9A (0.73) | RAB9ANPC1GRIN2BTP53THRB | |
| SCHEMBL1574412 | 0.86 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2GRIN2BTP53 | |
| SCHEMBL11058349 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2GRIN2BTHRB | |
| SCHEMBL1575119 | 0.85 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2GRIN2BTP53 | |
| SCHEMBL1575897 | 0.84 | GRIN2B (0.58) | RAB9ANPC1GRIN2BTP53THRB | |
| SCHEMBL1575550 | 0.82 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2GRIN2BTP53 | |
| SCHEMBL1575451 | 0.81 | GRIN2B (0.69) | RAB9ANPC1SMN1; SMN2GRIN2BTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | RAB9A 898/4885NPC1 413/4885SMN1; SMN2 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.